Page last updated: 2024-10-25

clonidine and Precordial Catch

clonidine has been researched along with Precordial Catch in 2 studies

Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.

Research Excerpts

ExcerptRelevanceReference
"Imipramine improved the symptoms of patients with chest pain and normal coronary angiograms, possibly through a visceral analgesic effect."9.07Imipramine in patients with chest pain despite normal coronary angiograms. ( Black, BC; Cannon, RO; Geraci, MF; Gracely, RH; Mincemoyer, R; Quyyumi, AA; Smith, WB; Stine, AM; Uhde, TW; Waclawiw, MA, 1994)
"Imipramine improved the symptoms of patients with chest pain and normal coronary angiograms, possibly through a visceral analgesic effect."5.07Imipramine in patients with chest pain despite normal coronary angiograms. ( Black, BC; Cannon, RO; Geraci, MF; Gracely, RH; Mincemoyer, R; Quyyumi, AA; Smith, WB; Stine, AM; Uhde, TW; Waclawiw, MA, 1994)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cannon, RO1
Quyyumi, AA1
Mincemoyer, R1
Stine, AM1
Gracely, RH1
Smith, WB1
Geraci, MF1
Black, BC1
Uhde, TW1
Waclawiw, MA1
King, MH1
Richards, DW1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Pain Measurement in Healthy Volunteers[NCT00001597]40 participants Observational1997-03-31Completed
Psychophysiological Interactions in Non-Cardiac Chest Pain[NCT00005575]Phase 30 participants Interventional1999-01-31Completed
WISE Ancillary Study Data Analyses: Efficacy of Hormone Replacement on Myocardial Ischemia in Postmenopausal Women With Normal/Minimal Coronary Artery Disease: Data Analysis[NCT00600106]37 participants (Actual)Interventional1999-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Endothelial Dysfunction (FMD)

"Endothelial dysfunction refers to altered vasoactive, anticoagulant, and anti-inflammatory properties of endothelium, and dysregulated vascular growth remodeling that results from a loss of nitric oxide (NO) bioactivity in the endothelium. Brachial Artery Reactivity Testing (BART), high-frequency ultrasonographic imaging of the brachial artery, evaluates flow-mediated vasodilation (FMD), an endothelium-dependent function. The technique provokes the release of nitric oxide, resulting in vasodilation that can be quantitated as an index of endothelial dysfunction.~Flow-mediated vasodilation is typically expressed as the change in post-stimulus diameter as a percentage of the baseline diameter [diameter after cuff deflation - baseline diameter / baseline diameter) x 100]." (NCT00600106)
Timeframe: Baseline

Interventionpercentage of pre-stimulus diameter (Mean)
Hormone Replacement Therapy8.2
Placebo8.8

Endothelial Dysfunction (FMD)

"Endothelial dysfunction refers to altered vasoactive, anticoagulant, and anti-inflammatory properties of endothelium, and dysregulated vascular growth remodeling that results from a loss of nitric oxide (NO) bioactivity in the endothelium. Brachial Artery Reactivity Testing (BART), high-frequency ultrasonographic imaging of the brachial artery, evaluates flow-mediated vasodilation (FMD), an endothelium-dependent function. The technique provokes the release of nitric oxide, resulting in vasodilation that can be quantitated as an index of vasomotor function.~Flow-mediated vasodilation is typically expressed as the change in post-stimulus diameter as a percentage of the baseline diameter [diameter after cuff deflation - baseline diameter / baseline diameter) x 100]." (NCT00600106)
Timeframe: 12 weeks

Interventionpercentage of pre-stimulus diameter (Mean)
Hormone Replacement Therapy8.8
Placebo7.3

Inducible Myocardial Ischemia

Inducible myocardial ischemia measured by P-31 gated magnetic resonance cardiac spectroscopy (MRS) is reported as change (∆) in PCr/ATP ratio, with isometric submaximal handgrip stress. PCr/ATP ratio defined as (stress-[average of rest and recovery periods]) / average of rest and recover periods X 100, and expressed as % mean ± SD. For this trial, myocardial ischemia was pre-specified as a fall in quantitative PCR/ATP ratio >20% from rest, and a lower value is considered indicative of greater ischemia. (NCT00600106)
Timeframe: 12 weeks

Interventionpercent change in PCR/ATP ratio (Mean)
Hormone Replacement Therapy-7.7
Placebo1.1

Inducible Myocardial Ischemia

Inducible myocardial ischemia measured by P-31 gated magnetic resonance cardiac spectroscopy (MRS) is reported as change (∆) in PCr/ATP ratio, with isometric submaximal handgrip stress. PCr/ATP ratio defined as (stress-[average of rest and recovery periods]) / average of rest and recover periods X 100, and expressed as % mean ± SD. For this trial, myocardial ischemia was pre-specified as a fall in quantitative PCR/ATP ratio >20% from rest, and a lower value is considered indicative of greater ischemia. (NCT00600106)
Timeframe: Baseline

Interventionpercent changed in PCR/ATP ratio (Mean)
Hormone Replacement Therapy-13.8
Placebo-7.0

Physical Functional Disability - Functional Capacity (Exercise Induced ST Segment Depression)

"Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain.~In electrocardiography, the ST segment connects the QRS complex and the T wave and has duration of 80 to 120 ms. It should be essentially level with the PR and TP segment. The normal ST segment has a slight upward concavity. Flat, downsloping, or depressed ST segment may indicate coronary ishcemia. Positive treadmill exercise stress test (>1.0 mm horizontal / downsloping or >1.5 upsloping ST segment depression measured 0.08 msec after the J point)." (NCT00600106)
Timeframe: Baseline

Interventionmm (Mean)
Hormone Replacement Therapy-0.79
Placebo-0.79

Physical Functional Disability - Functional Capacity (Metabolism Equivalents)

Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain. (NCT00600106)
Timeframe: Baseline

Interventionmetabolism equivalents (Mean)
Hormone Replacement Therapy6.1
Placebo5.8

Physical Functional Disability - Functional Capacity (Metabolism Equivalents)

Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain. (NCT00600106)
Timeframe: Exit (12 weeks)

Interventionmetabolism equivalents (Mean)
Hormone Replacement Therapy6.1
Placebo5.4

Physical Functional Disability - Functional Capacity (METs)

Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain. A MET is defined as the resting metabolic rate, that is, the amount or oxygen consumet at rest, sitting quietly in a chair, approximately 3.5 ml O2 / kg / min (1.2 kcallmin for a 70-kg person). As such, work at METs requires twice the resting metabolism or 7.0 ml O2/kg/min, and so on. (NCT00600106)
Timeframe: Baseline

Interventionmetabolism equivalents (Mean)
Hormone Replacement Therapy5.4
Placebo5.4

Physical Functional Disability - Functional Capacity (METs)

Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain. A MET is defined as the resting metabolic rate, that is, the amount or oxygen consumet at rest, sitting quietly in a chair, approximately 3.5 ml O2 / kg / min (1.2 kcallmin for a 70-kg person). As such, work at METs requires twice the resting metabolism or 7.0 ml O2/kg/min, and so on. (NCT00600106)
Timeframe: Exit at 12 weeks

Interventionmetabolism equivalents (Mean)
Hormone Replacement Therapy6.1
Placebo5.4

Physical Functional Disability - Functional Capacity (Stress Induced ST Segment Depression)

"Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain.~In electrocardiography, the ST segment connects the QRS complex and the T wave and has duration of 80 to 120 ms. It should be essentially level with the PR and TP segment. The normal ST segment has a slight upward concavity. Flat, downsloping, or depressed ST segment may indicate coronary ishcemia. Positive treadmill exercise stress test (>1.0 mm horizontal / downsloping or >1.5 upsloping ST segment depression measured 0.08 msec after the J point)." (NCT00600106)
Timeframe: Exit (12 weeks)

Interventionmm (Mean)
Hormone Replacement Therapy-1.05
Placebo-0.63

Quality of Life - Health Survey

"Quality of life assessed by cardiac symptoms and psychological questionnaires (SF 36 scale - Short Form Health Survey) The SF-36 includes one multi-item scale that assesses eight health concepts: 1) limitations in physical activities because of health problems; 2) limitations in social activities because of physical or emotional problems; 3) limitations in usual role activities because of physical health problems; 4) bodily pain; 5) general mental health (psychological distress and well-being); 6) limitations in usual role activities because of emotional problems; 7) vitality (energy and fatigue); and 8) general health perceptions.~Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability." (NCT00600106)
Timeframe: 12 weeks

,
Interventionunits on a scale (Mean)
Physical functioningRole-physicalRole-emotionalBodily painGeneral healthMental healthVitalitySocial functioning
Hormone Replacement Therapy59.458.876.554.555.266.435.659.4
Placebo44.425.066.741.557.269.341.256.1

Quality of Life - Health Survey

"Quality of life assessed by cardiac symptoms and psychological questionnaires (SF 36 scale - Short Form Health Survey) The SF-36 includes one multi-item scale that assesses eight health concepts: 1) limitations in physical activities because of health problems; 2) limitations in social activities because of physical or emotional problems; 3) limitations in usual role activities because of physical health problems; 4) bodily pain; 5) general mental health (psychological distress and well-being); 6) limitations in usual role activities because of emotional problems; 7) vitality (energy and fatigue); and 8) general health perceptions.~Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability." (NCT00600106)
Timeframe: Baseline

,
Interventionunits on a scale (Mean)
Physical functioningRole-physicalRole-emotionalBodily painGeneral healthMental healthVitalitySocial functioning
Hormone Replacement Therapy60.854.270.353.355.466.735.659.4
Placebo43.837.366.742.157.465.742.953.2

Quality of Life - Menopause Symptoms

Quality of life assessed by menopausal symptoms and psychological questionnaires (NCT00600106)
Timeframe: 12 weeks

,
Interventionpercent of participants (Number)
Hot flushes or flashingPoor memoryChange in sexual desireVaginal drynessAvoiding intimacy
Hormone Replacement Therapy4159353524
Placebo8978676756

Quality of Life - Menopause Symptoms

Quality of life assessed by menopausal symptoms and psychological questionnaires (NCT00600106)
Timeframe: Baseline

,
Interventionpercent of participants (Number)
Hot flushes or flashingPoor memoryChange in sexual desireVaginal drynessAvoiding intimacy
Hormone Replacement Therapy8976504439
Placebo6853375837

Trials

1 trial available for clonidine and Precordial Catch

ArticleYear
Imipramine in patients with chest pain despite normal coronary angiograms.
    The New England journal of medicine, 1994, May-19, Volume: 330, Issue:20

    Topics: Adult; Aged; Chest Pain; Chronic Disease; Clonidine; Coronary Angiography; Coronary Disease; Double-

1994
Imipramine in patients with chest pain despite normal coronary angiograms.
    The New England journal of medicine, 1994, May-19, Volume: 330, Issue:20

    Topics: Adult; Aged; Chest Pain; Chronic Disease; Clonidine; Coronary Angiography; Coronary Disease; Double-

1994
Imipramine in patients with chest pain despite normal coronary angiograms.
    The New England journal of medicine, 1994, May-19, Volume: 330, Issue:20

    Topics: Adult; Aged; Chest Pain; Chronic Disease; Clonidine; Coronary Angiography; Coronary Disease; Double-

1994
Imipramine in patients with chest pain despite normal coronary angiograms.
    The New England journal of medicine, 1994, May-19, Volume: 330, Issue:20

    Topics: Adult; Aged; Chest Pain; Chronic Disease; Clonidine; Coronary Angiography; Coronary Disease; Double-

1994
Imipramine in patients with chest pain despite normal coronary angiograms.
    The New England journal of medicine, 1994, May-19, Volume: 330, Issue:20

    Topics: Adult; Aged; Chest Pain; Chronic Disease; Clonidine; Coronary Angiography; Coronary Disease; Double-

1994
Imipramine in patients with chest pain despite normal coronary angiograms.
    The New England journal of medicine, 1994, May-19, Volume: 330, Issue:20

    Topics: Adult; Aged; Chest Pain; Chronic Disease; Clonidine; Coronary Angiography; Coronary Disease; Double-

1994
Imipramine in patients with chest pain despite normal coronary angiograms.
    The New England journal of medicine, 1994, May-19, Volume: 330, Issue:20

    Topics: Adult; Aged; Chest Pain; Chronic Disease; Clonidine; Coronary Angiography; Coronary Disease; Double-

1994
Imipramine in patients with chest pain despite normal coronary angiograms.
    The New England journal of medicine, 1994, May-19, Volume: 330, Issue:20

    Topics: Adult; Aged; Chest Pain; Chronic Disease; Clonidine; Coronary Angiography; Coronary Disease; Double-

1994
Imipramine in patients with chest pain despite normal coronary angiograms.
    The New England journal of medicine, 1994, May-19, Volume: 330, Issue:20

    Topics: Adult; Aged; Chest Pain; Chronic Disease; Clonidine; Coronary Angiography; Coronary Disease; Double-

1994

Other Studies

1 other study available for clonidine and Precordial Catch

ArticleYear
Near syncope and chest tightness after administration of apraclonidine before argon laser iridotomy.
    American journal of ophthalmology, 1990, Sep-15, Volume: 110, Issue:3

    Topics: Aged; Argon; Chest Pain; Clonidine; Female; Humans; Intraocular Pressure; Iris; Laser Therapy; Posto

1990